Molence· @MolenceBio · X·· 17 天前AI 评分57
AI 导读
Molence 公布其 Mol-1 工作流设计的 VHH 在六小时报告基因实验中可激活 4-1BB,两款 VHH-Fc 融合设计的 EC50 分别为 0.05 和 0.22 nM,对照 Utomilumab 为 0.43 nM。VHH 01 的 SPR KD 为 3.5 nM,两款设计均表现出高单体纯度、热稳定性和低自相互作用。该设计的目的是实现受体激动。
正文 · 原文
6/15 ⚡ Designed VHHs can activate 4-1BB.
In a six-hour reporter assay, two Mol-1-workflow designs tested as VHH-Fc fusions achieved activation EC50 values of 0.05 and 0.22 nM, compared with 0.43 nM for Utomilumab.
VHH 01 also showed an SPR KD of 3.5 nM. Both designs had favorable biophysical profiles, including high monomeric purity, thermal stability and low self-interaction.
The design objective here was receptor agonism.
#DrugDiscovery
5/15 🔁 One round of experimental feedback. A functional hit rate of 7% → 85%. For 4-1BB, we used first-round experimental results to guide a second design round: • Round 1: 2/30 functional hits • Round 2: 51/60 functional hits At 0.03 nM, 48 of the 51 second-round agonists exceeded the mean activation of the Utomilumab positive control. These VHH-Fc results show how experimental feedback can expand the pool of functional designs. #ProteinDesign在 X 查看被引用的帖子
来源:Molence · x.com